U.S. markets open in 2 hours 54 minutes
  • S&P Futures

    4,290.75
    -7.50 (-0.17%)
     
  • Dow Futures

    33,824.00
    -49.00 (-0.14%)
     
  • Nasdaq Futures

    13,655.00
    -26.25 (-0.19%)
     
  • Russell 2000 Futures

    2,020.60
    -3.20 (-0.16%)
     
  • Crude Oil

    88.86
    -0.55 (-0.62%)
     
  • Gold

    1,789.90
    -8.20 (-0.46%)
     
  • Silver

    20.01
    -0.26 (-1.29%)
     
  • EUR/USD

    1.0134
    -0.0031 (-0.30%)
     
  • 10-Yr Bond

    2.7910
    0.0000 (0.00%)
     
  • Vix

    20.08
    +0.55 (+2.82%)
     
  • GBP/USD

    1.2020
    -0.0038 (-0.31%)
     
  • USD/JPY

    134.1120
    +0.8400 (+0.63%)
     
  • BTC-USD

    24,078.70
    -96.33 (-0.40%)
     
  • CMC Crypto 200

    572.70
    -18.06 (-3.06%)
     
  • FTSE 100

    7,549.36
    +40.21 (+0.54%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Live Conference Call and Webcast at 4:30 p.m. EDT

SOUTH SAN FRANCISCO, Calif., August 01, 2022--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2022 financial results after market close on Monday, August 8, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial results and provide a corporate update.

Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13730293. A live audio webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company's website for 30 days following the live webcast.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005025/en/

Contacts

Investors
Eric Hyllengren
805-395-9669
ehyllengren@atarabio.com

Media
Alex Chapman
805-456-4772
achapman@atarabio.com